{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T18:44:14Z","timestamp":1764701054046,"version":"build-2065373602"},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Chest Medicine"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.ccm.2023.08.002","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T14:08:34Z","timestamp":1693836514000},"page":"45-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Monitoring of Sarcoidosis"],"prefix":"10.1016","volume":"45","author":[{"given":"Vasileios","family":"Kouranos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Athol Umfrey","family":"Wells","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.ccm.2023.08.002_bib1","doi-asserted-by":"crossref","first-page":"1602419","DOI":"10.1183\/13993003.02419-2016","article-title":"Prevalence and incidence of interstitial lung diseases in a multi-ethnic county of Greater Paris","volume":"50","author":"Duchemann","year":"2017","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.002_bib2","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/thoraxjnl-2020-216732","article-title":"Global and regional burden of interstitial lung disease and pulmonary sarcoidosis from 1990 to 2019: results from the Global Burden of Disease study 2019","volume":"77","author":"Ma","year":"2022","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.002_bib3","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1164\/ajrccm.160.2.ats4-99","volume":"160","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.002_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/thoraxjnl-2019-214348","article-title":"BTS Clinical Statement on pulmonary sarcoidosis","volume":"76","author":"Thillai","year":"2021","journal-title":"Thorax"},{"key":"10.1016\/j.ccm.2023.08.002_bib5","doi-asserted-by":"crossref","unstructured":"Ryerson CJ, Corte TJ, Lee JS,et\u00a0al. A standardized diagnostic ontology for fibrotic interstitial lung disease: an international working group perspective. Am J Respir Crit Care Med 2017;196:1249\u20131254.","DOI":"10.1164\/rccm.201702-0400PP"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.002_bib6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2023.08.002_bib7","series-title":"Clinical respiratory medicine","first-page":"647","article-title":"Approach to diagnosis of diffuse lung disease","author":"Wells","year":"2004"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.002_bib8","doi-asserted-by":"crossref","first-page":"2004079","DOI":"10.1183\/13993003.04079-2020","article-title":"ERS clinical practice guidelines on treatment of sarcoidosis","volume":"58","author":"Baughman","year":"2021","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.002_bib9","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1164\/rccm.202106-1366CI","article-title":"Management of advanced pulmonary sarcoidosis","volume":"205","author":"Gupta","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2023.08.002_bib10","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ccm.2015.08.003","article-title":"The diagnosis of sarcoidosis","volume":"36","author":"Govender","year":"2015","journal-title":"Clin Chest Med"},{"key":"10.1016\/j.ccm.2023.08.002_bib11","first-page":"167","article-title":"Sarcoidosis: a long-term follow up study","volume":"17","author":"Chappell","year":"2000","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.002_bib12","first-page":"123","article-title":"Outcome of pulmonary sarcoidosis: a population-based study 1976-2013","volume":"35","author":"Ungprasert","year":"2018","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.002_bib13","first-page":"29","article-title":"Sarcoidosis: epidemiology and prognosis; a 15-year European study","volume":"130","author":"Hillerdal","year":"1984","journal-title":"Ann Rev Respir Dis"},{"key":"10.1016\/j.ccm.2023.08.002_bib14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.rmed.2017.09.003","article-title":"Toxicity risk from glucocorticoids in sarcoidosis patients","volume":"132","author":"Khan","year":"2017","journal-title":"Respir Med"},{"key":"10.1016\/j.ccm.2023.08.002_bib15","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in progressive fibrosing interstitial lung diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.002_bib16","first-page":"476","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial Lancet","volume":"9","author":"Behr","year":"2021","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.002_bib17","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.ccm.2023.08.002_bib18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMra2005230","article-title":"Spectrum of fibrotic lung diseases","volume":"383","author":"Wijsenbeek","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.002_bib19","doi-asserted-by":"crossref","first-page":"2102571","DOI":"10.1183\/13993003.02571-2021","article-title":"Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry","volume":"60","author":"Hambly","year":"2022","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.002_bib20","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.chest.2020.04.074","article-title":"Mixed ventilatory defects in pulmonary sarcoidosis: prevalence and clinical features","volume":"158","author":"Kouranos","year":"2020","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.002_bib21","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1183\/09031936.00166809","article-title":"Impaired lung compliance and DL,CO but no restrictive ventilatory defect in sarcoidosis","volume":"36","author":"Boros","year":"2010","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.002_bib22","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/thoraxjnl-2012-202640","article-title":"Forced vital capacity as a primary end point in idiopathic pulmonary fibrosis treatment trials: making a silk purse from a sow's ear","volume":"68","author":"Wells","year":"2013","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.002_bib23","first-page":"e2022011","article-title":"Value of pulmonary function testing identifying progressive pulmonary disease in fibrotic sarcoidosis: results of a prospective feasibility study","volume":"39","author":"Baughman","year":"2022","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.002_bib24","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S2213-2600(13)70276-5","article-title":"An integrated clinicoradiological staging system for pulmonary sarcoidosis: a case-cohort study","volume":"2","author":"Walsh","year":"2014","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.ccm.2023.08.002_bib25","doi-asserted-by":"crossref","first-page":"105997","DOI":"10.1016\/j.rmed.2020.105997","article-title":"Predictors of mortality in fibrosing pulmonary sarcoidosis","volume":"169","author":"Jeny","year":"2020","journal-title":"Respir Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.002_bib26","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.chest.2017.07.008","article-title":"Predictors of mortality in pulmonary sarcoidosis","volume":"153","author":"Kirkil","year":"2018","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.002_bib27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/s-0039-1684020","article-title":"Multidisciplinary evaluation in patients with lung disease associated with Connective Tissue disease","volume":"40","author":"Wells","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.002_bib28","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1378\/chest.12-2479","article-title":"Accuracy of individual variables in the monitoring of long-term change in pulmonary sarcoidosis as judged by serial high-resolution CT scan data","volume":"145","author":"Zappala","year":"2014","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.ccm.2023.08.002_bib29","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 Update. An official American thoracic Society and European respiratory Society Technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.002_bib30","doi-asserted-by":"crossref","first-page":"1702089","DOI":"10.1183\/13993003.02089-2017","article-title":"Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis","volume":"51","author":"Broos","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2023.08.002_bib31","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1378\/chest.116.2.424","article-title":"Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a doubleblind, placebo-controlled, multicenter study","volume":"116","author":"Pietinalho","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2023.08.002_bib32","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1164\/rccm.200603-402OC","article-title":"Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement","volume":"174","author":"Baughman","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2023.08.002_bib33","first-page":"201","article-title":"A\u00a0double-blind, randomized, placebo-controlled trial of infliximab in patients with active pulmonary sarcoidosis","volume":"23","author":"Rossman","year":"2006","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ccm.2023.08.002_bib34","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jpainsymman.2012.02.016","article-title":"Armodafinil for sarcoidosis associated fatigue: a double-blind, placebo-controlled, crossover trial","volume":"45","author":"Lower","year":"2013","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.ccm.2023.08.002_bib35","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1378\/chest.07-2952","article-title":"Double-blind, randomized trial of dexmethylphenidate hydrochloride for the treatment of sarcoidosis-associated fatigue","volume":"133","author":"Lower","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.ccm.2023.08.002_bib36","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1183\/09031936.00000914","article-title":"Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis","volume":"44","author":"Judson","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2023.08.002_bib37","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial","volume":"17","author":"Baughman","year":"2000","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ccm.2023.08.002_bib38","first-page":"51","article-title":"The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis","volume":"23","author":"Judson","year":"2006","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ccm.2023.08.002_bib39","first-page":"121","article-title":"Steroid sparing effects of pentoxifylline in pulmonary sarcoidosis","volume":"26","author":"Park","year":"2009","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"10.1016\/j.ccm.2023.08.002_bib40","first-page":"198","article-title":"Use of fluticasone in acute symptomatic pulmonary sarcoidosis","volume":"19","author":"Baughman","year":"2002","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.002_bib41","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.resinv.2022.02.009","article-title":"Lung function decline in sarcoidosis","volume":"60","author":"Tanizawa","year":"2022","journal-title":"Respir Investig"},{"key":"10.1016\/j.ccm.2023.08.002_bib42","first-page":"3624344","article-title":"Poor outcome and mortality in patients with lower lung-Dominant sarcoidosis","volume":"2023","author":"Tachibana","year":"2023","journal-title":"Can Respir J"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.002_bib43","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1164\/rccm.202206-1041ST","article-title":"Syndrome of combined pulmonary fibrosis and emphysema: an official ATS\/ERS\/JRS\/ALAT research statement","volume":"206","author":"Cottin","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.002_bib44","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2214\/ajr.185.2.01850333","article-title":"Pulmonary sarcoidosis: comparison of findings of inspiratory and expiratory high-resolution CT and pulmonary function tests between smokers and nonsmokers","volume":"185","author":"Terasaki","year":"2005","journal-title":"AJR Am J Roentgenol"},{"issue":"165","key":"10.1016\/j.ccm.2023.08.002_bib45","doi-asserted-by":"crossref","first-page":"220087","DOI":"10.1183\/16000617.0087-2022","article-title":"The 6-min walk test as a primary end-point in interstitial lung disease","volume":"31","author":"Harari","year":"2022","journal-title":"Eur Respir Rev"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.002_bib46","doi-asserted-by":"crossref","first-page":"1901747","DOI":"10.1183\/13993003.01747-2019","article-title":"Physiological predictors of survival in patients with sarcoidosis-associated pulmonary hypertension: results from an international registry","volume":"55","author":"Shlobin","year":"2020","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.002_bib47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.4103\/1817-1737.49414","article-title":"The six-minute walk test in patients with pulmonary sarcoidosis","volume":"4","author":"Alhamad","year":"2009","journal-title":"Ann Thorac Med"},{"key":"10.1016\/j.ccm.2023.08.002_bib48","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.hrtlng.2022.12.006","article-title":"Six-minute stepper test for evaluating functional exercise capacity in patients with sarcoidosis","volume":"58","author":"Zeren","year":"2023","journal-title":"Heart Lung"},{"key":"10.1016\/j.ccm.2023.08.002_bib49","doi-asserted-by":"crossref","first-page":"106801","DOI":"10.1016\/j.rmed.2022.106801","article-title":"The six-minute walk test in sarcoidosis associated pulmonary hypertension: results from an international registry","volume":"196","author":"Gupta","year":"2022","journal-title":"Respir Med"},{"issue":"4","key":"10.1016\/j.ccm.2023.08.002_bib50","doi-asserted-by":"crossref","first-page":"1700465","DOI":"10.1183\/13993003.00465-2017","article-title":"Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension","volume":"50","author":"Boucly","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2023.08.002_bib51","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1164\/rccm.201007-1179OC","article-title":"Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference","volume":"183","author":"du Bois","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ccm.2023.08.002_bib52","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.rmed.2015.04.008","article-title":"Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis","volume":"109","author":"Nathan","year":"2015","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.002_bib53","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1183\/09031936.00117710","article-title":"Exercise capacity, muscle strength and fatigue in sarcoidosis","volume":"38","author":"Marcellis 1","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2023.08.002_bib54","unstructured":"Desai SR, Nishanth S, Johannson KA et\u00a0al. Computed Tomographic Phenotypes in Pulmonary Sarcoidosis \u2014 Results of a Multinational Delphi Study. Lancet Respir Med, in press."},{"issue":"6","key":"10.1016\/j.ccm.2023.08.002_bib55","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1148\/rg.306105512","article-title":"Pulmonary sarcoidosis: typical and atypical manifestations at high-resolution CT with pathologic correlation","volume":"30","author":"Criado","year":"2010","journal-title":"Radiographics"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.002_bib56","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1183\/09031936.00227014","article-title":"Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis","volume":"46","author":"Vorselaars","year":"2015","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2023.08.002_bib57","first-page":"1823710","article-title":"The utility of 18F-FDG PET\/CT for monitoring response and predicting prognosis after glucocorticoids therapy for sarcoidosis","volume":"2018","author":"Chen","year":"2018","journal-title":"BioMed Res Int"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.002_bib58","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2213-2600(18)30064-X","article-title":"Pulmonary sarcoidosis","volume":"6","author":"Spagnolo","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.002_bib59","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/diagnostics11061089","article-title":"Health-related quality of life (HRQoL) in sarcoidosis: diagnosis, management, and Health outcomes","volume":"11","author":"Saketkoo","year":"2021","journal-title":"Diagnostics"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.002_bib60","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1080\/07853890.2022.2063375","article-title":"Comorbidities of sarcoidosis","volume":"54","author":"Tana","year":"2022","journal-title":"Ann Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.002_bib61","first-page":"2","article-title":"Patient reported outcome measures (PROMs) in sarcoidosis","volume":"34","author":"Thunold","year":"2017","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.002_bib62","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/MCP.0000000000000981","article-title":"Patterns of progression in non-IPF fibrotic interstitial lung disease","volume":"29","author":"Wells","year":"2023","journal-title":"Curr Opin Pulm Med"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.002_bib63","doi-asserted-by":"crossref","first-page":"2002718","DOI":"10.1183\/13993003.02718-2020","article-title":"Progressive fibrosing interstitial lung disease: a clinical cohort (the PROGRESS study)","volume":"57","author":"Nasser","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ccm.2023.08.002_bib64","doi-asserted-by":"crossref","first-page":"790204","DOI":"10.3389\/fphar.2021.790204","article-title":"Outcomes and incidence of PF-ILD according to different definitions in a real-world setting","volume":"12","author":"Torrisi","year":"2021","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.ccm.2023.08.002_bib65","doi-asserted-by":"crossref","first-page":"2101396","DOI":"10.1183\/13993003.01396-2021","article-title":"Lung function trajectory in progressive fibrosing interstitial lung disease","volume":"59","author":"Oldham","year":"2022","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.002_bib66","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1164\/rccm.202201-0124OC","article-title":"Validation of proposed criteria for progressive pulmonary fibrosis","volume":"207","author":"Pugashetti","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.ccm.2023.08.002_bib67","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1164\/rccm.202206-1166LE","article-title":"SLF. Walsh. Progressive pulmonary fibrosis: putting the cart before the horse","volume":"206","author":"Johannson","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.ccm.2023.08.002_bib68","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in Adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.ccm.2023.08.002_bib69","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1164\/rccm.202206-1143LE","article-title":"AU. Wells. Progressive pulmonary fibrosis: should the timelines Be taken out of the definition?","volume":"206","author":"Cottin","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"10.1016\/j.ccm.2023.08.002_bib70","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.chest.2022.05.008","article-title":"The relationship of obesity and OSA to the development of sarcoidosis: a large retrospective case-control US veterans administration analysis","volume":"162","author":"Judson","year":"2022","journal-title":"Chest"},{"issue":"163","key":"10.1016\/j.ccm.2023.08.002_bib71","doi-asserted-by":"crossref","first-page":"210165","DOI":"10.1183\/16000617.0165-2021","article-title":"WASOG statement on the diagnosis and management of sarcoidosis-associated pulmonary hypertension","volume":"31","author":"Savale","year":"2022","journal-title":"Eur Respir Rev"},{"issue":"3","key":"10.1016\/j.ccm.2023.08.002_bib72","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1378\/chest.14-1475","article-title":"Sarcoidosis and cancer risk: systematic review and meta-analysis of observational studies","volume":"147","author":"Bonifazi","year":"2015","journal-title":"Chest"},{"issue":"19","key":"10.1016\/j.ccm.2023.08.002_bib73","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1136\/heartjnl-2019-316442","article-title":"Cardiac sarcoidosis: state-of-the-art review","volume":"107","author":"Kouranos","year":"2021","journal-title":"Heart"},{"issue":"12","key":"10.1016\/j.ccm.2023.08.002_bib74","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/j.jcmg.2016.11.019","article-title":"Complementary role of CMR to Conventional Screening in the diagnosis and prognosis of cardiac sarcoidosis","volume":"10","author":"Kouranos","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.002_bib75","first-page":"e21169","article-title":"The association of lung cancer and sarcoidosis: a systematic review","volume":"14","author":"Srinivasan","year":"2022","journal-title":"Cureus"},{"issue":"161","key":"10.1016\/j.ccm.2023.08.002_bib76","doi-asserted-by":"crossref","first-page":"210017","DOI":"10.1183\/16000617.0017-2021","article-title":"Lung transplantation for interstitial lung disease","volume":"30","author":"Kapnadak","year":"2021","journal-title":"Eur Respir Rev"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.002_bib77","first-page":"92","article-title":"Lung transplantation for pulmonary sarcoidosis","volume":"36","author":"Meyer","year":"2019","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"2","key":"10.1016\/j.ccm.2023.08.002_bib78","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/bmjspcare-2018-001575","article-title":"Barriers to specialist palliative care in interstitial lung disease: a systematic review","volume":"9","author":"Kim","year":"2019","journal-title":"BMJ Support Palliat Care"},{"issue":"12","key":"10.1016\/j.ccm.2023.08.002_bib79","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S2213-2600(17)30383-1","article-title":"Palliative care in interstitial lung disease: living well","volume":"5","author":"Kreuter","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.ccm.2023.08.002_bib80","doi-asserted-by":"crossref","first-page":"00065","DOI":"10.1183\/23120541.00065-2016","article-title":"What patients with pulmonary fibrosis and their partners think: a live, educative survey in The Netherlands and Germany","volume":"3","author":"van Manen","year":"2017","journal-title":"ERJ Open Res"}],"container-title":["Clinics in Chest Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523123000710?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272523123000710?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:16:46Z","timestamp":1759454206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272523123000710"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S0272523123000710"],"URL":"https:\/\/doi.org\/10.1016\/j.ccm.2023.08.002","relation":{},"ISSN":["0272-5231"],"issn-type":[{"type":"print","value":"0272-5231"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Monitoring of Sarcoidosis","name":"articletitle","label":"Article Title"},{"value":"Clinics in Chest Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ccm.2023.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2023 Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}